VTN and glaucoma: While several reports have proposed that basal activation of the classical and alternative complement pathway in eye tissue significantly contributes to its immune privilege, there is also a body of evidence demonstrating the presence of regulatory complement compounds such as C1 inhibitor, complement factor H, vitronectin, and clusterin in glaucoma patients [110,119,120].